Introduction {#Sec1}
============

In recent years, various types of synthetic cannabinoids \[[@CR1]--[@CR4]\] and cathinones \[[@CR5]--[@CR8]\] have become widely distributed, and are now causing social problems throughout many parts of the world. Nowadays, the newly emerging drugs seem to have become more potent than the previous ones, and sometimes cause deaths \[[@CR9]--[@CR12]\].

During the latter part of 2014, three herbal blend products, all of which were open, were brought to our laboratory for analysis, together with a cadaver. At the time of autopsy, the primary cause of death was considered to be 5-fluoro-ADB poisoning, as this compound was detected in the stomach contents and in five solid tissues; 5-fluoro-ADB was detected at a concentration of 49.2 ± 2.46 mg/g in the "GM sapphire" product, one of the three herbal blends \[[@CR13]\]. At that time, however, we noticed unknown peaks other than 5-fluoro-ADB in the gas chromatography-mass spectrometry (GC-MS) chromatograms for extracts of the three herbal blend products. We consulted the Cayman Spectral Library \[[@CR14]\], but it did not suggest any compounds. Shortly after the autopsy, we re-examined the herbal blend extracts for the presence of other drug(s) using matrix-assisted laser desorption ionization (MALDI) tandem quadrupole time-of flight (QTOF) mass spectrometry. The MALDI tandem QTOF mass spectra strongly suggested the presence of 5-fluoro-ADB-PINACA and MAB-CHMINACA without their reference standards. After obtaining the reference standards, we compared the mass spectra of the extracts of the herbal blend products with those of the reference standards using both GC--MS and liquid chromatography--tandem mass spectrometry (LC--MS--MS). The mass spectra of the herbal blend extracts coincided with those of the reference standards, disclosing the presence of 5-fluoro-ADB-PINACA in "AL 37" and "AP 31" and MAB-CHMINACA in "GM sapphire" \[[@CR15]\]; we then quantitated the concentrations of both compounds in the herbal blend products using the standard addition method. The concentrations of 5-fluoro-ADB-PINACA were 19.4 ± 0.55 and 19.0 ± 0.47 mg/g (mean ± standard deviation of triplicate determinations) for the herbal product brands "AL 37" and "AP 31," respectively; that of MAB-CHMINACA was 133 ± 4.5 mg/g for the "GM sapphire" blend product \[[@CR15]\].

In this communication, we identify and quantitate MAB-CHMINACA in various human specimens collected during autopsy. Unfortunately, however, 5-fluoro-ADB-PINACA was only detected in the stomach contents. To our knowledge, this is the first report to identify and quantitate the new synthetic cannabinoid MAB-CHMINACA from biological specimens.

Case history {#Sec2}
============

Human specimens were collected during the latter part of 2014 from the same deceased individual as described for demonstration of 5-fluoro-ADB \[[@CR13]\]; specimens were stored at −80 °C. The deceased was a 30-year-old man found in his room. Three opened, silver-colored herbal blend packages with brand names "AL 37," "AP 31" and "GM sapphire" were found nearby. Additional details of the case history are described in our previous report \[[@CR13]\].

Materials and methods {#Sec3}
=====================

Materials {#Sec4}
---------

The reference standards MAB-CHMINACA \[synonym: ADB-CHMINACA, *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide\], 5-fluoro-ADB-PINACA, AB-CHMINACA (internal standard, IS), and 5-fluoro-AB-PINACA (IS) were purchased from Cayman Chemical (Ann Arbor, MI, USA). All chemical structures of the above four synthetic cannabinoids are described in our previous report \[[@CR15]\]. Other common chemicals used were of the highest purity commercially available. Plastic centrifuge tubes with caps (5-ml capacity, 6 × 1.5 cm external diameter) and stainless beads (5 mm external diameter) for crushing solid tissues were purchased from TAITEC, Saitama, Japan. QuEChERS dispersive-SPE centrifuge tubes with caps (2-ml capacity), each of which contained 25 mg of primary secondary amine (PSA), 25 mg of end-capped octadecylsilane (C~18EC~), and 150 mg of magnesium sulfate, and Captiva ND Lipids cartridges (3-ml capacity) were purchased from Agilent (Santa Clara, CA, USA).

Whole blood specimens from the right and left atria and femoral vein, pericardial fluid, urine, stomach contents, and nine solid tissue specimens (brain, lung, heart muscle, liver, spleen, kidney, pancreas, skeletal muscle and adipose tissue) were collected from the deceased at autopsy and kept frozen at −80 °C until analysis; the adipose tissue specimen was obtained from the abdominal subcutaneous area.

Extraction procedure for human specimens {#Sec5}
----------------------------------------

For analysis of MAB-CHMINACA, AB-CHMINACA was used as the IS; for that of 5-fluoro-ADB-PINACA, 5-fluoro-AB-PINACA was used. The extraction procedure included crushing each specimen with a bead beater-type homogenizer, QuEChERS dispersive solid-phase extraction, and filtration through a Captiva ND lipids cartridge. Among the solid tissues, some modified steps were added to the regular extraction procedure for the adipose tissue specimen, the details of which are described in our previous report \[[@CR13]\].

LC--MS--MS conditions {#Sec6}
---------------------

LC--MS--MS conditions were exactly the same as those described in the previous report \[[@CR13]\] except that ion transitions were *m*/*z* 371 → 241 for MAB-CHMINACA, *m*/*z* 357 → 241 for AB-CHMINACA (IS), *m*/*z* 363 → 318 for 5-fluoro-ADB-PINACA, and *m*/*z* 349 → 304 for 5-fluoro-AB-PINACA (IS); the fragmentor voltage and collision energy were 120 and 25 V for MAB-CHMINACA, 120 and 21 V for AB-CHMINACA, 120 and 9 V for 5-fluoro-ADB-PINACA, and 120 and 9 V for 5-fluoro-AB-PINACA, respectively.

Standard addition method {#Sec7}
------------------------

The standard addition method is frequently used for analysis by atomic absorption spectroscopy \[[@CR16]\]. Because this method does not require a blank matrix and completely overcomes matrix effects, we used it to analyse compound(s) in human specimens with quite different properties \[[@CR11]--[@CR13], [@CR17]--[@CR20]\]. Method principles and examples of the standard addition calibration curve were discussed in detail in our previous report \[[@CR21]\].

Matrix effects and recovery rates {#Sec8}
---------------------------------

In our previous report \[[@CR13]\] for analysis of 5-fluoro-ADB in human specimens, we used the heart muscle and adipose tissue as example matrices to demonstrate the matrix effects and recovery rates; in the present study, we used femoral vein blood and the liver as example matrices for analysis of MAB-CHMINACA. Other conditions of this experiment and the calculation method were the same as described previously \[[@CR13]\].

Results and discussion {#Sec9}
======================

Identification trial for 5-fluoro-ADB-PINACA and MAB-CHMINACA {#Sec10}
-------------------------------------------------------------

The extracts from all specimens were subjected to detection of peaks of 5-fluoro-ADB-PINACA by LC--MS--MS in various detection modes. The protonated molecular ion at *m*/*z* 363 could not be detected in any specimens of the deceased. However, in the selected reaction monitoring (SRM) mode, a very small peak at *m*/*z* 318 \[above the limit of detection (LOD) and the below the limit of quantitation (LOQ)\] could be detected only for the stomach contents; for all other specimens, any peak at *m*/*z* 318 was below the LOD in the SRM mode.

In contrast to 5-fluoro-ADB-PINACA in the specimens, the concentrations of MAB-CHMINACA were found at much higher concentrations than those of 5-fluoro-ADB-PINACA. It was possible to obtain product ion mass spectra from femoral vein whole blood and liver tissue specimens. Figure [1](#Fig1){ref-type="fig"} shows an example of product ion mass spectra obtained from the extracts of femoral vein whole blood and liver tissue in comparison with that of the reference standard MAB-CHMINACA. The spectra obtained from the two extracts coincided with that of the reference standard MAB-CHMINACA, with no impurity peaks, confirming the detected compound was MAB-CHMINACA.Fig. 1Product ion mass spectra of the extracts of femoral vein whole blood and liver tissue specimens collected from the deceased in comparison with that of the reference standard MAB-CHMINACA, recorded by liquid chromatography--tandem mass spectrometry (LC--MS--MS) together with the probable fragmentation mode

Validation of the method {#Sec11}
------------------------

Figure [2](#Fig2){ref-type="fig"} shows an example of the SRM chromatograms for the target compound and the IS extracted from femoral vein whole blood and liver tissue. The target compound MAB-CHMINACA and IS AB-CHMINACA appeared at retention times of 8.72 and 7.93 min, respectively. The bottom panel of Fig. [2](#Fig2){ref-type="fig"} shows the absence of AB-CHMINACA in the liver tissue extract, though a very small peak was detected at the same retention time as that of AB-CHMINACA with 100-fold magnification of the vertical axis. It seems reasonable to regard the small peak as a carryover of the AB-CHMINACA spiked into the liver tissue just before the run without the spiking of the IS. It should be noted that the backgrounds were generally very low, and there were no impurity peaks interfering with the target or IS peaks.Fig. 2Selected reaction monitoring chromatograms using LC--MS--MS for the reference standard MAB-CHMINACA, the extracts of the femoral vein whole blood and liver tissue specimens, the internal standard (IS) AB-CHMINACA spiked into the liver tissue, and the extract of the liver tissue without addition of the IS

Table [1](#Tab1){ref-type="table"} shows the standard addition calibration equations for AMB-CHMINACA in 14 specimens, except for urine, in which the target compound was below the LOD. The correlation coefficients for all specimens were greater than 0.999. The LOD (signal-to-noise ratio ≥3) for the compound using the present method was around 0.1 ng/ml or g. The LOQ (signal-to-noise ratio ≥10) was around 0.5 ng/ml or g.Table 1Standard addition calibration equations for MAB-CHMINACA in body fluids and solid tissues of the deceasedSpecimenEquation^a^Correlation coefficient (*r*)Femoral vein blood*y* = 0.001353*x* + 0.0081940.9999Right heart blood*y* = 0.001359*x* + 0.014470.9999Left heart blood*y* = 0.001288*x* + 0.011990.9999Pericardial fluid*y* = 0.001259*x* + 0.018820.9995Stomach contents*y* = 0.001287*x* + 0.013580.9998Brain*y* = 0.001017*x* + 0.019950.9999Lung*y* = 0.001075*x* + 0.024160.9998Heart muscle*y* = 0.001224*x* + 0.033900.9999Liver*y* = 0.0009081*x* + 0.14140.9999Spleen*y* = 0.00100*x* + 0.017250.9998Kidney*y* = 0.0009232*x* + 0.036370.9998Pancreas*y* = 0.001081*x* + 0.034470.9999Skeletal muscle*y* = 0.001002*x* + 0.0098220.9999Adipose tissue*y* = 0.000246*x* + 0.0041830.9998^a^If *y* equals 0, the pre-existing concentration (*x*) can be calculated as a minus value

Because we employed the standard addition method for quantitation, without the use of blank specimens, it was impossible to present the usual accuracy and precision data. Instead, as shown in Table [2](#Tab2){ref-type="table"}, we repeated intraday and interday determinations of MAB-CHMINACA in the femoral vein whole blood and liver tissue specimens as an example. The repeatability, expressed as relative standard deviations, was not greater than 14.8 %.Table 2Examples of intraday and interday repeatability for determination of MAB-CHMINACA in postmortem femoral vein blood and in the liver of the deceasedSpecimenIntraday (*n* = 5)Interday (*n* = 5)Concentration found (ng/ml)^a^Repeatability (%RSD)Concentration found (ng/ml)^a^Repeatability (%RSD)Femoral vein blood6.05 ± 0.1853.056.48 ± 0.3635.60Liver156 ± 5.833.74166 ± 24.514.8*RSD* relative standard deviation^a^Data given as mean ± standard deviation (SD)

Although the standard addition method can overcome matrix effects and low recovery rates, we checked them under the present extraction conditions. In this study, we used acetonitrile deproteinization plus QuEChERS dispersive solid-phase extraction plus filtration through a Captiva ND Lipids cartridge coupled to an LC--MS--MS system. The matrix effects for MAB-CHMINACA were 76.9 ± 1.70 and 69.4 ± 2.17 % (*n* = 3 in each) for the femoral vein whole blood and liver tissue specimens, respectively. The recovery rates of the test compound calculated (for calculation method, see Ref. \[[@CR13]\]\]) were excellent at 88.8 ± 11.2 and 109 ± 5.82 % (*n* = 3 in each) for the femoral vein whole blood and liver tissue specimens, respectively.

Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of the deceased {#Sec12}
----------------------------------------------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows the postmortem distribution of MAB-CHMINACA in body fluids, stomach contents, and nine solid tissues. The concentration of the compound in urine was below the LOD (about 0.1 ng/ml), despite detection of the compound in whole blood specimens. This suggests that the interval between inhalation of MAB-CHMINACA and cardiac arrest was so short that the compound could not reach the urinary bladder via the kidney and ureter. In the previous studies, synthetic cannabinoids were reported to accumulate in the adipose tissue at higher concentrations \[[@CR9], [@CR13], [@CR22]\]. However, for MAB-CHMINACA in the present case, its concentration in the adipose tissue was not high, but was second from the lowest among the nine solid tissue specimens. This phenomenon may be also due to the shortness of interval between inhalation of the compound and cardiac arrest; it seems likely that it takes some time for MAB-CHMINACA to accumulate up to relatively high levels in the fat of the adipose tissue. The concentration of MAB-CHMINACA was outstandingly highest in the liver, followed by the kidney, pancreas and heart muscle.Table 3Concentrations of MAB-CHMINACA in body fluids and solid tissues of the deceasedSpecimenConcentration (ng/ml or g)Femoral vein blood6.05 ± 0.185Right heart blood10.6 ± 0.667Left heart blood9.30 ± 0.334Pericardial fluid14.9 ± 0.768Stomach contents10.6 ± 0.133UrineNDBrain19.6 ± 0.572Lung22.5 ± 1.29Heart muscle27.7 ± 0.933Liver156 ± 5.83Spleen17.2 ± 1.00Kidney39.4 ± 1.69Pancreas31.9 ± 0.415Skeletal muscle9.80 ± 0.28Adipose tissue17.0 ± 1.44Data given as mean ± SD obtained by triplicate determinations*ND* not detectable \[lower than the detection limit (0.1 ng/ml)\]

According to our previous study \[[@CR13]\], it is evident that this victim smoked the herbal blend of "GM sapphire." In another study \[[@CR15]\], we also disclosed a high concentration of MAB-CHMINACA from the same herbal blend item "GM sapphire," and here we detected MAB-CHMINACA from body fluid and solid tissue specimens collected from the same cadaver as used in the previous study \[[@CR13]\]. These results show that 5-fluoro-ADB and MAB-CHMINACA coexisted in the "GM sapphire" herbal blend that was smoked by the victim. It should be concluded, therefore, that 5-fluoro-ADB and MAB-CHMINACA synergically exerted their toxicities, leading to death after a short interval.

It seems useful to discuss the difference in distribution among the specimens collected from the same deceased for 5-fluoro-ADB and MAB-CHMINACA. In addition, the contents of both compounds in "GM sapphire" are known; they were 49.2 ± 2.46 \[[@CR13]\] and 133 ±4.5 mg/g \[[@CR15]\], respectively. The first point to be mentioned is the much higher concentrations of MAB-CHMINACA than those of 5-fluoro-ADB in the specimens; the concentrations of 5-fluoro-ADB were only 3.18, 1.90, 1.82, 1.17, 1.61 and 7.95 ng/g in stomach contents, the brain, heart muscle, spleen, pancreas and adipose tissue, respectively, and were below the LOD for body fluid specimens; very small peaks appeared for the lung, liver, kidney, and skeletal muscle, but they were below the LOQ \[[@CR13]\]. Even if we take into consideration the fact that the concentration of MAB-CHMINACA is 2.7-fold higher than that of 5-fluoro-ADB in the herbal blend product "GM sapphire,\" the concentrations of MAB-CHMINACA in various human specimens are much higher than the values expected (Table [3](#Tab3){ref-type="table"}) when compared with those of 5-fluoro-ADB \[[@CR13]\]. In addition, the concentrations of MAB-CHMINACA were 6.05--10.6 ng/ml in whole blood specimens, while those of 5-fluoro-ADB in whole blood were below the LOD. These differences in concentrations between the two compounds may be largely due to the stability of the compounds; MAB-CHMINACA has a primary amino group at the terminal part and a cyclohexylmethyl moiety attached to the nitrogen, both of which are much more stable and resistant to chemical decomposition and/or metabolism than the methoxy group and the 5-fluoropentyl moiety present in the 5-fluoro-ADB structure in an alive/dead human body.

Although the outstandingly high concentration of MAB-CHMINACA in the liver is difficult to explain, the second-highest concentration of the compound in the kidney (Table [3](#Tab3){ref-type="table"}) may be due to the ability of this compound to excrete into urine via the kidney, while the concentration of 5-fluoro-ADB in the kidney was below the LOQ \[[@CR13]\]. This contrast seems to be due to the hydrophilic nature of the compounds; MAB-CHMINACA is more hydrophilic due to the presence of a primary amino group than is 5-fluoro-ADB with the methoxy group.

Conclusions {#Sec13}
===========

In the present study, we identified and quantitated MAB-CHMINACA in human specimens collected from the same victim as used in the previous study on the demonstration of 5-fluoro-ADB. The concentration of MAB-CHMINACA was outstandingly highest in the liver, followed by the kidney, pancreas and heart muscle. The compound was also detected in whole blood and pericardial fluid, but not in urine. To our knowledge, this is the first report to demonstrate MAB-CHMINACA from biological/human specimens.
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